The pulmonary arterial hypertension market was valued at USD 691.55 Million in 2024 driven by the rising incidence of hypertension and diabetes across the 8 major markets. It is expected to grow at a CAGR of 5.21% during the forecast period of 2025-2034 and attain a market value of USD 1149.20 Million by 2034.
Base Year
Historical Year
Forecast Year
One of the major market trends include an increasing preference for oral therapies, which is reshaping the pulmonary arterial hypertension treatment landscape by enhancing patient comfort and adherence, driving the market growth.
In July 2023, Keros Therapeutics received FDA clearance to initiate the Phase 2 TROPOS trial of KER-012 for pulmonary arterial hypertension. Such developments are expected to boost the market value in the forecast period.
The United States is expected to lead the market, supported by its advanced healthcare infrastructure, significant pharmaceutical R&D investments, and widespread adoption of advanced therapies.
Pulmonary arterial hypertension is a rare and progressive condition characterized by elevated blood pressure in the pulmonary arteries, often leading to heart failure. The market is impacted by advancements in targeted therapies such as endothelin receptor antagonists and PDE-5 inhibitors, alongside trends in precision medicine and oral formulations. These developments are boosting the demand for innovative and patient-centric treatment solutions.
Rising Incidence of Kidney Disease Drives Market Growth
The rising prevalence of conditions associated with pulmonary arterial hypertension, including obesity, hypertension, and diabetes, is fueling market growth. According to the Centers for Disease Control and Prevention (CDC) report, approximately 14% of U.S. adults, or 35.5 million people, were affected by chronic diseases such as hypertension and diabetes in 2023. These comorbidities significantly contribute to the onset and progression of pulmonary arterial hypertension, underscoring the need for advanced therapeutic interventions. This growing burden has highlighted the demand for effective therapies and interventions, intended to improve patient outcomes for the management of pulmonary arterial hypertension.
Several trends and developments are being observed in the market to enhance the current situation. Some of the trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
Market Breakup by Route of Administration
Market Breakup by Type
Market Breakup by Distribution Channel
Market Breakup by Region
Segmentation Based on the Route of Administration to Witness Substantial Market Growth
Based on the route of administration the market is divided into oral, intravenous/ subcutaneous, and others. Among these, oral administration is expected to lead the market share due to its convenience and patient-friendly nature, particularly in outpatient settings. Oral medications, such as Posumit (macitentan) and Adempas (riociguat), offer ease of use, reducing the need for hospital visits, high patient compliance, and cost-effectiveness. Additionally, advancements in oral formulation are enhancing bioavailability and treatment outcomes, further fueling the growth of this segment throughout the forecast period.
Based on region, the market report covers the United States, Germany, France, Italy, Spain, the United Kingdom, Japan, and India. Among these, the United States is expected to dominate the market due to its robust healthcare infrastructure and a strong presence of prominent pharmaceutical companies. The robust research and development activities in the pharmaceutical and biotechnology sectors have led to continuous advancements in pulmonary arterial hypertension, driving a high market value in the region.
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Founded in 1863 and headquartered in Leverkusen, Germany, Bayer AG provides Adempas, an oral treatment for pulmonary arterial hypertension. As a soluble guanylate cyclase pathway activator, Adempas enhances exercise capacity and alleviates symptoms, establishing Bayer as a key player in pulmonary arterial hypertension therapy development.
Founded in 1849 and based in New York, Pfizer specializes in the development of Revatio for pulmonary arterial hypertension. This phosphodiesterase-5 inhibitor improves blood flow in the lungs and enhances exercise capacity, playing a pivotal role in pulmonary arterial hypertension treatment.
Established in 2000 and headquartered in Brentford, United Kingdom, GSK markets Volibris (ambrisentan) for the treatment of pulmonary arterial hypertension. This endothelin receptor antagonist reduces pulmonary artery blood pressure, aiding symptom management and improving patient quality of life.
Founded in 1876 and headquartered in Indianapolis, Indiana, Eli Lilly manufactures Adcirca, a treatment for pulmonary arterial hypertension. As a phosphodiesterase-5 inhibitor, Adcirca improves pulmonary blood flow and exercise capacity, highlighting Eli Lilly's significant contribution to pulmonary arterial hypertension therapies.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other companies include United Therapeutics Corporation, Actelion Pharmaceuticals (Johnson & Johnson), Novartis AG, Amgen Inc., Gilead Sciences Inc., and Teva Pharmaceutical Industries Ltd.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by Type |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share